1. Home
  2. ATNI vs MXCT Comparison

ATNI vs MXCT Comparison

Compare ATNI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATN International Inc.

ATNI

ATN International Inc.

HOLD

Current Price

$27.84

Market Cap

406.5M

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.23

Market Cap

93.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNI
MXCT
Founded
1987
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
406.5M
93.0M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
ATNI
MXCT
Price
$27.84
$1.23
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$5.50
AVG Volume (30 Days)
55.9K
1.2M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
4.03%
N/A
EPS Growth
34.29
N/A
EPS
N/A
N/A
Revenue
$727,975,000.00
$33,026,000.00
Revenue This Year
$3.12
N/A
Revenue Next Year
$1.10
$18.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.86
$0.64
52 Week High
$30.45
$2.40

Technical Indicators

Market Signals
Indicator
ATNI
MXCT
Relative Strength Index (RSI) 57.39 72.82
Support Level $22.76 $0.72
Resistance Level $29.24 $1.75
Average True Range (ATR) 1.05 0.09
MACD 0.17 0.02
Stochastic Oscillator 74.64 91.77

Price Performance

Historical Comparison
ATNI
MXCT

About ATNI ATN International Inc.

ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: